Objective: It is well known that RARC with intracorporeal diversion is being increasingly performed worldwide. In this article, we review the current situation of the intracorporeal neobladder.

Methods: We discuss the principles of intracorporeal orhotopic diversion, focusing on the most relevant: The Karolinska-modified Studer neobladder, the University of Southern California-modified Studer neobladder. The pyramid pouch and the modified Y-shaped orthotopic neobladder. We also compare functional and perioperative outcomes from our series and the available studies regarding RARC and intracorporeal orthotopic diversion. 

Results: Review of existing literature suggests that RARC with totally intracorporeal neobladder, in some cases, has improved operative,  postoperative, and functional outcomes, becoming a safe and feasible alternative to ORC.

Conclusions: The results from the intraorporeal neobladders series appear to be promising, but high-quality randomized controlled trials comparing to ICUD to ECUD should be performed in order to define the advantages and  disadvantages of totally intracorporeal urinary diversion and its future role in the treatment of invasive bladder cancer.